{"classes":[{"categories":[{"measurements":[{"comment":"NA=OS upper limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG000","lowerLimit":"6.1","upperLimit":"NA","value":"23.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"OS was defined as the time from first dose of study treatment to death due to any cause. OS was calculated from product-limit (Kaplan-Meier) method for censored data. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants from the pooled Cohort 5 received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg or 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles.","id":"OG000","title":"Pooled Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"All participants pooled from the Cohort 5 (pembrolizumab + 20 or 25 mg doses of lenalidomide) with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation. The analysis was pre-specified to be a pooled analysis of all participants grouped by disease cohort (DLBCL) and treatment combination (irrespective of dose); therefore data by individual dose were not analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Overall Survival (OS) in Participants Pooled From Cohort 5 (Pembrolizumab + 20 or 25 mg Doses of Lenalidomide) Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)","type":"SECONDARY","unitOfMeasure":"Months"}